Efficacy of Intravenous Lidocaine on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy

Sponsor
West China Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04295330
Collaborator
(none)
260
1
2
26.9
9.7

Study Details

Study Description

Brief Summary

Patients who meet the enrollment criteria will be randomized 1:1 to either the lidocaine or the placebo group.

In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. In the placebo group, the same volume of normal saline will be administered during anesthesia.

Condition or Disease Intervention/Treatment Phase
  • Drug: Lidocaine Hydrochloride, Injectable
  • Drug: 0.9% normal saline
N/A

Detailed Description

Patients who meet the enrollment criteria will be randomized 1:1 to either the lidocaine or the placebo group.

In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline. In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml. All the background infusions of PCIA will set at 2 ml/h, the bolus volume of each PCIA press is 2 ml and the lockout interval is 15 min.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
260 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The experimental group received lidocaine and the control group received the same amount of saline.The experimental group received lidocaine and the control group received the same amount of saline.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
The participants, the anesthesiologist, data collectors, the physicians performing the follow-up, and data analysts will be blinded to the group allocation. Blinding will maintain until the completion of the final analyses.
Primary Purpose:
Treatment
Official Title:
Efficacy of Prolonging Intravenous Lidocaine by 72 Hours on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy: a Prospective Randomized Controlled Study
Actual Study Start Date :
Feb 27, 2020
Anticipated Primary Completion Date :
Dec 27, 2021
Anticipated Study Completion Date :
May 27, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Lidocaine group

at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery.

Drug: Lidocaine Hydrochloride, Injectable
In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
Other Names:
  • lidocaine group
  • Placebo Comparator: placebo group

    the same volume of normal saline will be administered during anesthesia.

    Drug: 0.9% normal saline
    In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
    Other Names:
  • placebo group
  • Outcome Measures

    Primary Outcome Measures

    1. The primary outcome is the incidence of moderate to severe pain (NRS ≥ 4) during movement (i.e. deep breathing) at 24 hours after surgery. [The first 24 hours after surgery]

      The pain is evaluated using numerical rating scale(NRS). NRS scores range from 0 to 10 points, with 0 points representing no pain, 1-3 points representing mild pain, 4-6 points representing moderate pain, 7-9 points representing severe pain and 10 points representing the strongest pain.

    Secondary Outcome Measures

    1. The incidence of moderate to severe pain at 24 hours after surgery at rest [The first 24 hours after surgery]

      The pain is evaluated using numerical rating scale(NRS). NRS scores range from 0 to 10 points, with 0 points representing no pain, 1-3 points representing mild pain, 4-6 points representing moderate pain, 7-9 points representing severe pain and 10 points representing the strongest pain.

    2. The incidence of moderate to severe pain at 48 and 72 hours after surgery at rest and during movement; [At 3 days after surgery]

      The pain is evaluated using numerical rating scale(NRS). NRS scores range from 0 to 10 points, with 0 points representing no pain, 1-3 points representing mild pain, 4-6 points representing moderate pain, 7-9 points representing severe pain and 10 points representing the strongest pain.

    3. The cumulative morphine consumption at 24, 48 and 72 hours postoperatively [At the end of the surgery,24,48 and 72 hours after surgery]

      intra-operative and postoperative opioid use is reported as morphine milligram equivalents, calculated using the Practical Pain Management calculator

    4. Bowel function recovery [At 3 days after surgery]

      defined as the time to first defecation or time to first flatus

    5. The incidence of PONV during the first 72 hours after surgery [At 3 days after surgery]

      we considered it PONV if patients felt any nausea or had any vomiting

    6. The incidence of a composite of postoperative pulmonary complications during hospitalization [during the period from the end of surgery to discharge]

      defined as positive if any component developed before discharge after surgery; These complications included respiratory infection, respiratory failure, pleural effusion, atelectasis, pneumothorax, bronchospasm, or aspiration pneumonitis loading dose, immediately after the end of surgery, and at the first 24 hours after surgery

    7. Length of hospital stay [during the period from the end of surgery to discharge]

      determined by the number of days from admittance to discharge

    8. Patient satisfaction scores [72 hours after surgery and before discharge]

      (satisfaction scores regarding pain control and the overall recovery process were obtained at 72 hours after surgery, using a 11-point Likert scale, with 0 indicating "very dissatisfied"and10 indicating "very satisfied"

    9. Levels of inflammatory factors ( IL-6, TNF-α) at 24 hours after surgery. [at 24 hours after surgery.]

      Levels of inflammatory factors ( IL-6, TNF-α) at 24 hours after surgery.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age: 18-80 years old

    • American Society of Anesthesiologists(ASA) Ⅰ~III

    • patients scheduled for elective hepatectomy

    Exclusion Criteria:

    • body weight < 40 kg or >100 kg; metastases occurring in other distant organs; severe hepatic insufficiency (aspartate aminotransferase or alanine transaminase or bilirubin > 2.5 times the upper limit of normal), renal impairment (creatinine clearance < 60 ml/min); cardiac rhythm disorders or systolic heart failure (second-and third-degree heart block, ejection fraction < 50%); with allergies to any of the trial drugs; inability to comprehend numeric rating scale.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 West China Hospital Chengdu Sichuan China 610041

    Sponsors and Collaborators

    • West China Hospital

    Investigators

    • Study Director: Chunling Jiang, PhD, West China Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Chunling Jiang, Professor, West China Hospital
    ClinicalTrials.gov Identifier:
    NCT04295330
    Other Study ID Numbers:
    • 2018HXFH046
    First Posted:
    Mar 4, 2020
    Last Update Posted:
    Sep 16, 2021
    Last Verified:
    May 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 16, 2021